To treat complex valvular heart disease,cardiovascular conduits are necessary.These conduits can be made from artificial materials,valved homograft conduits(VHC),or valved xenograft conduits.VHC offer physiological advantages,including resistance to calcification and infection,and do not require lifelong anticoagulation,making them highly compatible with the human body.However,the shortage of donors and the inability to store VHC for a long time have impeded their widespread adoption.The cryopreservation technology is expected to solve this problem.This article reviews the progress in donor selection,preservation methods,and clinical applications of VHC,providing valuable insights for its reconstruction of left and right ventricular outflow tract in clinical use.
国家科技期刊平台
NSTL
万方数据
